Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
KNSA Price/Volume Stats
| Current price | $20.59 | 52-week high | $28.15 |
| Prev. close | $20.49 | 52-week low | $16.56 |
| Day low | $20.20 | Volume | 592,600 |
| Day high | $20.69 | Avg. volume | 397,777 |
| 50-day MA | $22.87 | Dividend yield | N/A |
| 200-day MA | $21.91 | Market Cap | 1.49B |
KNSA Stock Price Chart Interactive Chart >
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
KNSA Price Returns
| 1-mo | -2.37% |
| 3-mo | -19.70% |
| 6-mo | 9.11% |
| 1-year | 12.88% |
| 3-year | 58.63% |
| 5-year | 67.67% |
| YTD | 17.39% |
| 2023 | 17.09% |
| 2022 | 27.27% |
| 2021 | -33.39% |
| 2020 | 59.76% |
| 2019 | -60.63% |
Loading social stream, please wait...